Vivani Medical, Inc.VANI
Metabolic10 cited findings · profile updated 2026-08-25
1.41 USDnot live — refreshed daily
1 Day
-0.7%
5 Day
+1.4%
1 Month
+7.6%
3 Month
+10.2%
About Vivani Medical, Inc.
Vivani Medical, Inc. (VANI) is focused on metabolic therapeutic areas. The company is studying NPM-139 in a Phase 1 trial, SLIM-1, for metabolic indications. This trial is an open-label, active-controlled study conducted in Australia.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Trial Phase | Phase 1 for SLIM-1 (NPM-139) | Vivani Medical, Inc. — SEC 8-K (2026-08-06), p.1 |
| Comparator arm | Wegovy (semaglutide injection) in SLIM-1 (NPM-139) | Vivani Medical, Inc. — SEC 8-K (2026-08-06), p.1 |
| NPM-139 arm size | 10 participants in SLIM-1 (NPM-139) | Vivani Medical, Inc. — SEC 8-K (2026-08-06), p.2 |
| Wegovy arm size | 10 participants in SLIM-1 (NPM-139) | Vivani Medical, Inc. — SEC 8-K (2026-08-06), p.2 |
| Trial duration | four-week for SLIM-1 | Vivani Medical, Inc. — SEC 8-K (2026-08-13), p.4 |
| Wegovy dose | 0.25 mg/week in SLIM-1 (NPM-139) | Vivani Medical, Inc. — SEC 8-K (2026-08-06), p.2 |
Key projects
- NPM-139 (metabolic) — Australia
NPM-139 is being studied in the Phase 1 SLIM-1 trial in Australia.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Metabolic research library →